secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2026-07-02T20:20:52+00:00
Accession:  0001193125-26-294613
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology raises $50M upfront in private placement; warrants could add $64M
--------------------------------------------------------------------------------

- Gross proceeds of ~$50M from 19.6M shares at $2.551/share; warrants at $3.289 for additional ~$64M if exercised.
- Financing led by BVF Partners with GordonMD, RTW Investments, Coastlands Capital; expected close July 2, 2026.
- Proceeds extend cash runway into Q2 2027; support MICVO Phase 1 monotherapy and Phase 1/2 combination studies.
- Updated Phase 1 monotherapy data for 2L+ R/M HNSCC expected Fall 2026; Phase 1/2 combo data in Q4 2026.
- Warrants exercisable upon earlier of public disclosure of MICVO Phase 1 data or Oct 1, 2026; expire July 2, 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526294613/0001193125-26-294613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526294613/pyxs-20260630.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-294613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer